Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials

Annals of Internal Medicine

Volumn 119, Issue 2, 1993, Pages 136-145

  Atkins, David ^a,b   Psaty, Bruce M ^a   Koepsell, Thomas D ^a,c   Longstreth Jr , W T ^a,d   Larson, Eric B ^a,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Office of Disease Prevention and Health Promotion   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; COLESTYRAMINE; GEMFIBROZIL; NICOTINIC ACID;

CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; FAT INTAKE; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE;

ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR DISORDERS; CHOLESTEROL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027380992     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-119-2-199307150-00008     Document Type: Article

References (92)

1. Dyken ML, Wolf PA, Barnett HJ, Bergan JJ, Mass WK, Kannel WB, et al. Risk factors in stroke. A statement for physicians by the Subcommittee on Risk Factors and Stroke of the Stroke Council. Stroke. 1984;15:1105-11.
2. Yatsu FM, Fisher M. Atherosclerosis: current concepts on pathogenesis and interventional therapies. Ann Neurol. 1989;26:3-12.
3. Gordon T, Kannel WB, Castelli WP, Dawber TR. Upoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med. 1981;141:1128-31.
4. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet. 1992;39:344-7.
5. Chen ZM, Collins R, Peto R, Li WX. Serum cholesterol levels and stroke mortality. N Engl J Med. 1989;321:1339-41.
6. Reed D, Yano K, Kagan A. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. Am J Med. 1986;80:871-8.
7. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-10.
8. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol con-centrations and mortality: a quantitative overview of primary prevention trials. Br Med J. 1990;301:309-14.
9. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259-63.
10. Hulley SB, Walsh JM, Newman TB. Health policy on blood cholesterol-time. Time to change directions. Circulation. 1992;86:1026-9.
11. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J. 1992;304:431-4.
12. National Center for Health Services Research. Health, United States, 1990. Hyattsville, Maryland: Public Health Service; 1991.
13. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge, Massachusetts: Harvard University Press; 1984.
14. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-51.
15. Sacks HS, Berrier J, Reitman D, Acona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med. 1987; 316:450-5.
16. Miettinen M, Turpeinen O, Karvonen MJ, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. Lancet. 1972;2:835-8.
17. Turpeinen O, Karvoven MJ, Pekkarinen M, Miettinen M, Elosuo R, Paavilainen E. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. Int J Epidemiol. 1979;8:99-118.
18. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-24.
19. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
20. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40.
21. Kornitzer M, De Backer G, Dramaix M, Kittel F, Thilly C, Graffar M, et al. Belgian Heart Disease Prevention Project: incidence and mortality results. Lancet. 1983;1:1066-70.
22. Rose G, Tunstall-Pedoe HD, Heller RF. UK Heart Disease Prevention Project: incidence and mortality results. Lancet. 1983;1:1062-6.
23. World Health Organization European Collaborative Group. Multifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results. Eur Heart J. 1983;4:141-7.
24. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis. 1972;15:177-83.
25. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-55.
26. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-24.
27. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-9.
28. Yusuf S, Furberg CD. Single factor trials: Control through life-style changes. In: Olsson AG; ed. Atherosclerosis: Biology and Clinical Science. New York: Churchill Livingstone; 1987:389-92.
29. Yusuf S, Cutler J. Single factor trials: drug studies. In: Olsson AG; ed. Atherosclerosis: Biology and Clinical Science. New York: Churchill Livingstone; 1987:393-7.
30. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-18.
31. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
32. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a prior hypotheses of the trial. JAMA. 1990;263:1795-801.
33. Strandberg TE, Salomaa W, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA. 1991;256:1225-9.
34. WHO Cooperative Trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984;2:600-4.
35. WHO Cooperative Trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1980;2:379-85.
36. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-71.
37. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
38. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30.
39. Rothman KJ. Modern Epidemiology. Boston: Little, Brown and Company; 1986:189-221.
40. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a Research Committee of the Scottish Society of Physicians. Br Med J. 1971;790:775-84.
41. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist C, Blacket RB. Low fat, low cholesterol diet in the secondary prevention of coronary heart disease. Adv Exp Med Biol. 1978;109:317-30.
42. Rose GA, Thomson WB, Williams RT. Corn oil in treatment of ischaemic heart disease. Br Med J. 1965;1:1531-3.
43. Research Committee to the Medical Research Council. Low-fat diet in myocardial infarction. A controlled trial. Lancet. 1965;2:501-4.
44. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J. 1971;4:767-75.
45. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-54.
46. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317: 1237-45.
47. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis. 1978;31:5-14.
48. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069-118.
49. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled trial of a diet high in unsaturated fat. Circulation. 1969; 40(Suppl II):II1-II62.
50. Frantz ID, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 1989; 9:129-35.
51. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
52. Controlled trial of soya-bean oil in myocardial infarction. Report of a Research Committee to the Medical Research Council. Lancet. 1968;2:693-700.
53. Leren P. The effect of plasma cholesterol lowering diets in male survivors of myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl. 1966;466:1-92.
54. The Coronary Drug Project: Findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA. 1973;226:652-7.
55. Hjermann I, Velve Byre K, Holme I, Leren I. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomized trial in healthy men. Lancet. 1981;2:1303-10.
56. Multiple Risk Factor interventional trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-77.
57. Miettinen TA, Huttunen JK, Naukkarinen V, Strandberg T, Mattila S, Kumlin T, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. JAMA. 1985;254:2097-102.
58. Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Interventional Trial. Am J Cardiol. 1986;58:1-13.
59. Dyer AR, Stamler J, Paul O, Shekelle RB, Schoenberger JA, Berkson DM, et al. Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis. 1981;34:249-60.
60. Marquardsen J. Epidemiology of strokes in Europe. In: Barnett HJ; ed. Stroke: Pathophysiology, Diagnosis and Management. New York: Churchill Livingstone; 1986:19-43.
61. Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins and cerebrovascular atherosclerosis. A review. Stroke. 1988;19:423-30.
62. Mathew NT, Davis D, Meyer JS, Chandar K. Hyperlipoproteinemia in occlusive cerebrovascular disease. JAMA. 1975;232:262-6.
63. Lin CH, Shimizu Y, Kato H, Robertson TL, Furonaka H, Kodama, et al. Cerebrovascular disease in a fixed population of Hiroshima and Nagasaki, with special reference to relationship between type and risk factors. Stroke. 1984;15:653-60.
64. Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of stroke in Japan and Hawaii. Stroke. 1984;15:15-23.
65. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteberg, Sweden. Stroke. 1990; 21:223-9.
66. Corwin LI, Wolf PA, Kannel WB, McNamara PM. Accuracy of death certification of stroke: the Framingham Study. Stroke. 1982; 13:818-21.
67. Iso H, Jacobs DR Jr, Goldman L. Accuracy of death certificate diagnosis of intracranial hemorrhage and nonhemorrhagic stroke. The Minnesota Heart Survey. Am J Epidemiol. 1990;132:993-8.
68. Qizilbash N, Duffy SW, Rohan TE. Repeat measurement of case-control data: Correcting risk estimates for misclassification due to regression dilution of lipids in transient ischemic attacks and minor ischemic stroke. Am J Epidemiol. 1991;133:832-8.
69. Adams RJ, Carroll RM, Nichols FT, McNair N, Feldman DS, Feldman EB, et al. Plasma lipoproteins in cortical versus lacunar infarction. Stroke. 1989;20:448-52.
70. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-6.
71. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990;131:579-88.
72. Hennerici M, Kleophas W, Gries FA. Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke. 1991; 22:989-92.
73. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project - 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990;53:16-22.
74. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989;20: 1460-5.
75. Ueshima H, Iida M, Shimamoto T, Konishi M, Tsujioka K, Tanigaki M, et al. Multivariate analysis of risk factors for stroke. Eight-year follow-up study of farming villages in Akita, Japan. Prev Med. 1980;9:722-40.
76. Tanaka H, Hayashi M, Date C, Imai K, Asada M, Shoji H, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke. 1985;16:773-80.
77. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled biennial measurements. The Framingham Heart Study: an epidemiologic investigation of cardiovascular disease. Section 34. (NIH Publication no, 87-2703). Washington DC: U.S. Department of Health and Human Services; 1987.
78. Tandon N, Harmon J, Robard D, Jamieson GA. Thrombin receptors define responsiveness of cholesterol modified platelets. J Biol Chem. 1983;258:11840-5.
79. Yamori Y, Horie R, Ohtaka M, Nara Y, Fukase M. Effect of hypercholesterolemic diet on the incidence of cerebrovascular and myocardial lesions in spontaneously hypertensive rats (SHR). Clin Exp Pharmacol Physiol. 1976;(Suppl 3):205-8.
80. Reed D, Jacobs D, Hayashi T, Iso H, Konishi M, Nelson J, et al. Comparison of intracerebral arterionecrosis in Japanese men in Japan and Hawaii [Abstract]. Circulation. 1992;85:A1.
81. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1988;318:262-4.
82. Simpson IA, Lorimer Ar, Walker ID, Davidson JF. Effects of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemost. 1985;54:442-4.
83. Fletcher A, Alkjaersig N, Schonfeld G, Witztum J. Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings. Arteriosclerosis. 1981;1:202-9.
84. Stringer MD, Steadman CA, Kakkar W. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions. Curr Med Res Opin. 1990;12:207-14.
85. Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Tremoli E, et al. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. J Lab Clin Med. 1987;110:279-86.
86. Dickersin K, Hewitt P, Mutch L, Chalmers I, Chalmers TC. Perusing the literature: comparison of MEDLINE searching with a perinatal clinical trials database. Controlled Clin Trials. 1985;6:306-17.
87. Dickersin K, Chan SS, Chalmers TC, Sacks HS, Smith H. Publication bias and clinical trials. Controlled Clin Trials. 1987;8:343-53.
88. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-72.
89. Roussouw JE, Lewis B, Rifkind BM. Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol lowering [Letter], N Engl J Med. 1992;325:1813.
90. Fagard R. Serum cholesterol and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. Am J Med. 1991;90:62S-63S.
91. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med. 1990;113:916-20.
92. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, Neaton J, et al. Report of the conference on low blood cholesterol: Mortality association. Circulation. 1992;86:1046-60.